Reperfusion therapy for ST-elevation myocardial infarction complicated by cardiogenic shock: the European Society of Cardiology EurObservational programme acute cardiovascular care-European association of PCI ST-elevation myocardial infarction registry

Abstract

Aims To determine the current state of the use of reperfusion and adjunctive therapies and in-hospital outcomes in European Society of Cardiology (ESC) member and affiliated countries for patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS). Methods and results ESC EurObservational Research Programme prospective international cohort study of admissions with STEMI within 24 h of symptom onset (196 centres; 26 ESC member and 3 affiliated countries). Of 11 462 patients enrolled, 448 (3.9) had CS. Patients with compared to patients without CS, less frequently received primary percutaneous coronary intervention (PCI) (65.5 vs. 72.2) and fibrinolysis (15.9 vs. 19.0), and more often had no reperfusion therapy (19.0 vs. 8.5). Mechanical support devices (intraaortic ballon pump 11.2, extracoporeal membrane oxygenation 0.7, other 1.1) were used infrequently in CS. Bleeding definition academic research consortium 2-5 bleeding complications (10.1 vs. 3.0, P < 0.01) and stroke (4.2 vs. 0.9, P < 0.01) occurred more frequently in patients with CS. In-hospital mortality was 10-fold higher (35.5 vs. 3.1) in patients with CS. Mortality in patients with CS in the groups with PCI, fibrinolysis, and no reperfusion therapy were 27.4, 36.6, and 62.4, respectively. Conclusion In this multi-national registry, patients with STEMI complicated by CS less frequently receive reperfusion therapy than patients with STEMI without CS. Early mortality in patients with CS not treated with primary PCI is very high. Therefore, strategies to improve clinical outcome in STEMI with CS are needed.